2024-11-07 - Analysis Report
## Merck & Co., Inc. (MRK) Stock Analysis:

**1) Performance vs. S&P 500:**

Merck & Co., Inc. (MRK) is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines, vaccines, and animal health products. 

**MRK's cumulative return is 56.24%, significantly lower than the S&P 500's (VOO) cumulative return of 139.88%. This creates a substantial gap of -83.64%.** Although MRK is currently trading at a 2.89% percentile relative to its historical performance range (max: 22.62%, min: -86.8%), it still demonstrates a significant underperformance compared to the broader market.

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-----|-------|
| 2015-2017 | -1.6% | 18.1% | -31.8% | 0.9 |
| 2016-2018 | 45.6% | 17.0% | 20.9% | 0.7 |
| 2017-2019 | 51.2% | 17.0% | 8.1% | 0.7 |
| 2018-2020 | 45.5% | 27.2% | 6.4% | 0.7 |
| 2019-2021 | 6.3% | 27.2% | -83.6% | 0.6 |
| 2020-2022 | 26.3% | 27.2% | 8.6% | 0.5 |
| 2021-2023 | 41.1% | 19.8% | 12.3% | 0.3 |
| 2022-2024 | 31.0% | 23.2% | 7.3% | 0.3 |

* **CAGR:**  MRK's CAGR has fluctuated significantly over the years, demonstrating periods of strong growth and periods of underperformance.
* **MDD:** MRK's MDD has been relatively consistent, indicating a reasonable level of risk.
* **Alpha:** MRK's alpha has been largely negative, suggesting that the stock has not consistently outperformed the market.
* **Beta:**  MRK's beta has been steadily decreasing, indicating a diminishing correlation to the overall market and potentially implying lower risk.

**2) Recent Price Movement:**

* **Closing price:** 100.73
* **5-day moving average:** 101.69
* **20-day moving average:** 105.98
* **60-day moving average:** 111.99

**MRK's price is currently below all three moving averages, indicating a downtrend.**

**3) RSI, PPO, and Delta_Previous_Relative_Divergence:**

* **RSI:** 13.39 (Oversold)
* **PPO:** -0.3 (Negative)
* **Delta_Previous_Relative_Divergence:** -18.41 (Short-term downtrend)

**MRK is currently oversold, with a negative PPO and a short-term downtrend in its relative divergence. This suggests potential for a rebound, but continued downward pressure remains.**

**Expected Return:**

* **Expected Return:** 0.0%
* **This indicates that MRK's potential future return, based on historical data, is expected to be similar to the S&P 500 index over the long term (2+ years) for a buy-and-hold strategy.**

**4) Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2024-11-06 | 1.87 | 15.96 B$ |

**MRK's recent earnings have been mixed, with a slight decline in EPS in the latest quarter. This could be contributing to the current price weakness.**

**5) Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |
| 2023-09-30 | $15.96B | 73.29% |
| 2023-06-30 | $15.04B | 73.24% |

**MRK's revenue has remained relatively stable with strong profit margins, demonstrating its consistent profitability.**

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |
| 2023-09-30 | $41.25B | 11.50% |
| 2023-06-30 | $38.69B | -15.44% |

**MRK's equity has been growing steadily, but ROE has fluctuated, suggesting a need to analyze the specific factors driving these changes.**

**6) News and Recent Issues:**

* **You need to provide the specific date for me to analyze recent news articles and reports.** 
* **I can then analyze recent earnings news from sources like shacknews, provide market outlook, analyst opinions, and performance highlights from FINBOLD and other sources.**

**7) Overall Analysis:**

MRK is a stable company with a consistent revenue and profit stream. However, it is currently underperforming the market and experiencing a downtrend in price. The stock is oversold and has a negative PPO, suggesting potential for a rebound. However, the recent earnings report and the overall market sentiment may continue to put downward pressure on the stock. 

**Long-term investors may consider a buy-and-hold strategy as the stock's expected return is aligned with the S&P 500.** It is crucial to monitor the news, analyst opinions, and further financial data to make informed investment decisions.

**8) Report:**

**Merck & Co., Inc. (MRK) Stock Analysis**

**Company Overview:**

Merck & Co., Inc. (MRK) is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines, vaccines, and animal health products.

**Performance vs. S&P 500:**

MRK's current stock price is below all three moving averages, indicating a downtrend. Its cumulative return of 56.24% is significantly lower than the S&P 500's cumulative return of 139.88%, resulting in a gap of -83.64%. However, MRK is trading at a 2.89% percentile relative to its historical performance range, indicating a relative improvement compared to its past underperformance. 

**Alpha and Beta Analysis:**

MRK's CAGR has been volatile, displaying both strong growth and underperformance. Its MDD has remained stable, suggesting a reasonable level of risk. Alpha has been largely negative, indicating a lack of consistent market outperformance. The steady decrease in beta implies a diminishing correlation to the broader market and potentially lower risk.

**Recent Price Movement:**

MRK's stock price is currently below the 5-day, 20-day, and 60-day moving averages, further supporting the downtrend.

**Technical Indicators:**

MRK's RSI of 13.39 signals an oversold condition. The negative PPO of -0.3 and the short-term downtrend in relative divergence suggest potential for a rebound, but downward pressure persists.

**Expected Return:**

The expected return of 0.0% implies that MRK's potential future return is anticipated to be similar to the S&P 500 over the long term.

**Recent Earnings and Outlook:**

MRK's recent earnings have been mixed, with a slight decline in EPS in the latest quarter. This could be contributing to the current price weakness.

**Financial Information:**

MRK demonstrates consistent profitability, evident in stable revenue and strong profit margins. Equity has been steadily growing, but fluctuations in ROE require further analysis.

**News and Recent Issues:**

[Insert analysis of news articles and reports based on the provided date, focusing on earnings news, market outlook, analyst opinions, and performance highlights.]

**Overall Analysis:**

MRK, despite its stable business, is currently underperforming the market and experiencing a downtrend. Oversold conditions and a negative PPO signal potential for a rebound, but the recent earnings report and market sentiment may continue to exert downward pressure.

**Long-term investors may consider a buy-and-hold strategy given the stock's expected return aligned with the S&P 500.** However, continuous monitoring of news, analyst opinions, and financial data is crucial for informed investment decisions.
